Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Primary: To evaluate the safety and tolerability of long-term therapy with three dose levels (2, 5, 10 mg daily) of Lecozotan (SRA-333) SR administered to patients with mild to moderate Alzheimer’s Disease who have completed Week 12 evaluations of study 3098B1-201-EU [EudraCT No. 2005-001475-35].
Critère d'inclusion
- Alzheimer's disease